Carlos Carillo - SAB Biotherapeutics Senior Affairs
| SABS Stock | USD 2.94 0.02 0.68% |
Executive
Carlos Carillo is Senior Affairs of SAB Biotherapeutics
| Address | 2100 East 54th Street North, Sioux Falls, SD, United States, 57104 |
| Phone | 605 679 6980 |
| Web | https://www.sabbiotherapeutics.com |
SAB Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4611) % which means that it has lost $0.4611 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0325) %, meaning that it created substantial loss on money invested by shareholders. SAB Biotherapeutics' management efficiency ratios could be used to measure how well SAB Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.53 in 2024. Return On Capital Employed is likely to drop to -0.55 in 2024. At this time, SAB Biotherapeutics' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 2.7 M in 2024, whereas Total Assets are likely to drop slightly above 63.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Christian JD | Quantum Si incorporated | 52 | |
| David Lowenstein | CarMax Inc | N/A | |
| Marney Kadrmas | Knife River | 54 | |
| Johan Denecke | Quantum Si incorporated | N/A | |
| Romain Launay | SCOR PK | 43 | |
| Jeff Lambert | Knife River | N/A | |
| Katherine Atkinson | Quantum Si incorporated | N/A | |
| Ian Kelly | SCOR PK | 56 | |
| Andy Cramer | Knife River | N/A | |
| Jeremy Stover | Knife River | N/A | |
| Tony Spilde | Knife River | N/A | |
| Grace Johnston | Quantum Si incorporated | 41 | |
| Nancy Christenson | Knife River | 67 | |
| Alex Hutcheson | Quantum Si incorporated | N/A | |
| Jeffry Keyes | Quantum Si incorporated | 51 | |
| Juan Avendano | Quantum Si incorporated | N/A | |
Management Performance
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.46 |
SAB Biotherapeutics Leadership Team
Elected by the shareholders, the SAB Biotherapeutics' board of directors comprises two types of representatives: SAB Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SAB. The board's role is to monitor SAB Biotherapeutics' management team and ensure that shareholders' interests are well served. SAB Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SAB Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA CMA, Ex CFO | ||
| MD MBA, Executive Officer | ||
| Eddie Sullivan, President, CoFounder | ||
| Carlos Carillo, Senior Affairs | ||
| Christoph MBA, Executive COO | ||
| Michael King, EVP CFO | ||
| Samuel Reich, Executive Chairman | ||
| Christine MBA, CoFounder Director | ||
| Edward DVM, CoFounder Observer |
SAB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SAB Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.46 | ||||
| Operating Margin | (12.06) % | ||||
| Current Valuation | (11.47 M) | ||||
| Shares Outstanding | 9.23 M | ||||
| Shares Owned By Insiders | 19.15 % | ||||
| Shares Owned By Institutions | 36.91 % | ||||
| Number Of Shares Shorted | 33.92 K | ||||
| Price To Book | 0.75 X | ||||
| Price To Sales | 19.26 X |
Pair Trading with SAB Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if SAB Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with SAB Stock
Moving against SAB Stock
| 0.92 | NHC | National HealthCare | PairCorr |
| 0.8 | SEM | Select Medical Holdings | PairCorr |
| 0.79 | LLY | Eli Lilly | PairCorr |
| 0.76 | AMGN | Amgen Inc | PairCorr |
| 0.72 | PFE | Pfizer Inc Financial Report 6th of August 2024 | PairCorr |
The ability to find closely correlated positions to SAB Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace SAB Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back SAB Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling SAB Biotherapeutics to buy it.
The correlation of SAB Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as SAB Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if SAB Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for SAB Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.